<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706091</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003535</org_study_id>
    <nct_id>NCT04706091</nct_id>
  </id_info>
  <brief_title>Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia</brief_title>
  <official_title>Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to determine the effect of suvorexant on actigraphically-derived total&#xD;
      sleep time in patients with effectively treated restless legs syndrome with persistent&#xD;
      insomnia in a two-arm, double-blind, randomized placebo-controlled crossover 2.5-month trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restless Legs Syndrome (RLS) is a sensory-motor neurological disorder characterized by an&#xD;
      irresistible urge to move the legs. Persistent difficulties with all phases of sleep are&#xD;
      common in patients whose RLS symptoms are resolved with treatment. Multiple potential causes&#xD;
      for treatment-refractory sleep disturbance exist, including activating effects of dopamine&#xD;
      agonists (which are first-line RLS treatments), conditioned insomnia and poor sleep habits as&#xD;
      a result of chronic RLS-related sleep disturbance, and comorbid medical and psychiatric&#xD;
      illness. Suvorexant provides an important therapeutic option to treat insomnia in the context&#xD;
      of RLS. It has demonstrated long-term efficacy, particularly in shortening the duration of&#xD;
      nocturnal awakenings and increasing total sleep time. Similarly, it has a comparatively&#xD;
      benign side effect profile compared to many other agents typically prescribed to treat&#xD;
      insomnia. The investigators aim to determine the effect of suvorexant on&#xD;
      actigraphically-derived total sleep time, as well as actigraphically-derived wake after sleep&#xD;
      onset, Insomnia Severity Index score, subjective sleep endpoints, and RLS symptom severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 1:1 ratio to suvorexant 10-20 mg or equivalent placebo for four weeks followed by crossover (after a 2-week washout) to the alternate treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Actigraphically-Derived Total Sleep Time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total sleep time as measured by actigraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actigraphically-Derived Wake After Sleep Onset</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wake after sleep onset as measured by actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>2 weeks</time_frame>
    <description>A validated tool to measure insomnia severity, on a scale of 0-28, with a higher score representing greater insomnia severity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diary-Derived Wake After Sleep Onset</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wake after sleep onset as reported on daily sleep diaries</description>
  </other_outcome>
  <other_outcome>
    <measure>Diary-Derived Total Sleep Time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total sleep time as reported on daily sleep diaries</description>
  </other_outcome>
  <other_outcome>
    <measure>Diary-derived Sleep Onset Latency, Sleep Efficiency and Sleep Quality</measure>
    <time_frame>2 weeks</time_frame>
    <description>Sleep onset latency, sleep efficiency and sleep quality as reported on daily sleep diaries</description>
  </other_outcome>
  <other_outcome>
    <measure>International Restless Legs Syndrome Study Group Scale</measure>
    <time_frame>1 week</time_frame>
    <description>A validated tool to measure restless legs syndrome severity, on a scale of 0-40, with a higher score representing greater restless legs syndrome severity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <condition>Insomnia</condition>
  <condition>Sleep Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment --&gt; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo --&gt; Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>10-mg or 20-mg suvorexant capsules</description>
    <arm_group_label>Placebo --&gt; Treatment</arm_group_label>
    <arm_group_label>Treatment --&gt; Placebo</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo --&gt; Treatment</arm_group_label>
    <arm_group_label>Treatment --&gt; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women of any ethnic origin&#xD;
&#xD;
          2. Written informed consent is obtained&#xD;
&#xD;
          3. Speaks and writes in English&#xD;
&#xD;
          4. A willingness and ability to comply with study procedures&#xD;
&#xD;
          5. Age 25-85 years&#xD;
&#xD;
          6. Diagnosis of RLS via Cambridge-Hopkins RLS questionnaire&#xD;
&#xD;
          7. International Restless Legs Syndrome Study Group scale score (IRLS) &lt; 15&#xD;
&#xD;
          8. RLS treatment with a dopaminergic agonist or an alpha-2-delta agent&#xD;
&#xD;
          9. No changes in RLS medication in the previous month&#xD;
&#xD;
         10. DSM-5 criteria for Insomnia Disorder&#xD;
&#xD;
         11. Report a total sleep time ≤ 7 hours and wake after sleep onset (WASO) &gt; 45 minutes on&#xD;
             7 or more of the 14 nightly sleep logs during both the initial 2-week screening period&#xD;
             and the two-week screening run-in period. WASO does not decrease by more than 50% on&#xD;
             the 2-week sleep diary obtained between the screening visit and the randomization&#xD;
             visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of moderate/severe obstructive sleep apnea (AHI &gt; 30) not using continuous&#xD;
             positive airway pressure therapy (CPAP) (can be included if CPAP adherent), or other&#xD;
             untreated primary sleep disorders (e.g. narcolepsy)&#xD;
&#xD;
          2. Shift workers&#xD;
&#xD;
          3. Unwillingness to not use sedative-hypnotics (other than suvorexant) during the study&#xD;
             period&#xD;
&#xD;
          4. Unwillingness to maintain stable RLS medication during the study unless medically&#xD;
             indicated&#xD;
&#xD;
          5. Current use of an opiate medication&#xD;
&#xD;
          6. Unwillingness to not take stimulants (e.g. caffeine) after 4:00 pm during the study&#xD;
&#xD;
          7. Current major depressive episode, by report and as indicated by the Patient Health&#xD;
             Questionnaire (PHQ-9)&#xD;
&#xD;
          8. Lifetime history of bipolar disorder, psychosis, or other serious psychiatric illness&#xD;
&#xD;
          9. Current alcohol/substance use disorder&#xD;
&#xD;
         10. BMI ≥ 40 kg/m^2&#xD;
&#xD;
         11. Renal or hepatic disease judged to interfere with drug metabolism and excretion&#xD;
&#xD;
         12. Pregnancy or breastfeeding&#xD;
&#xD;
         13. Malignancy within past 2 years&#xD;
&#xD;
         14. Surgery within past 3 months&#xD;
&#xD;
         15. Neurological disorder or cardiovascular disease raising safety concerns about use of&#xD;
             suvorexant and/or judged to interfere with ability to assess efficacy of the treatment&#xD;
&#xD;
         16. Medical instability considered to interfere with study procedures&#xD;
&#xD;
         17. Concomitant medications with drug interaction or co-administration concerns&#xD;
&#xD;
         18. Contraindications or allergic responses to suvorexant&#xD;
&#xD;
         19. History of being treated with suvorexant&#xD;
&#xD;
         20. Travel across two time-zones during the week prior to enrollment&#xD;
&#xD;
         21. Greater than 6 cups of coffee per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Winkelman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin W Wipper</last_name>
    <phone>617-643-6026</phone>
    <email>bwipper@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin W Wipper</last_name>
      <phone>617-643-6026</phone>
      <email>bwipper@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>John Winkelman, MD, PhD</investigator_full_name>
    <investigator_title>Chief, Sleep Disorders Clinical Research Program</investigator_title>
  </responsible_party>
  <keyword>Suvorexant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

